Fulgent Genetics (FLGT) Q2 2026 Earnings Call Transcript
Fulgent Genetics (FLGT) reported Q2 2026 revenue of $85.4M, up 4% year over year and 20% sequentially, driven by Bako Diagnostics and StrataDX integration. Non-GAAP gross margin was 31.3% and Adjusted EBITDA was a $17.1M loss. Full-year revenue guidance was cut to $330M-$340M due to lower collection rates from a billing system transition.
How this was made
The 30-second read
Why it matters
The key tradable driver is the explicit full-year guidance reduction due to lower-than-anticipated collection rates from billing/claims processing delays, alongside ongoing customer volume loss as a major client moves testing in-house.
Market read
Investors get a fresh, company-specific earnings and guidance update, with the main risk centered on revenue-cycle execution and collections rather than demand collapse.
What to watch
The article also notes increased sequencing coverage (TruePath) and expansion of repeat targets, which could support future test demand even if near-term collections lag.
Background
Fulgent Genetics is a precision diagnostics and anatomic pathology services company, currently integrating acquisitions and transitioning revenue-cycle management systems.
Ticker impact
Fulgent reported Q2 results and revised full-year revenue guidance to $330M-$340M due to lower collection rates from a billing system transition.
Likely downside bias until investors gain confidence that billing/collection rates normalize; upside possible if later quarters show recovery.
The article discloses a concrete guidance reduction (revenue and non-GAAP EPS) explicitly linked to billing/claims processing delays, plus a continued headwind from a largest-customer volume loss.
Market effects
Highlights execution risk in lab/revenue-cycle software transitions, which can affect sentiment toward precision diagnostics and pathology service providers.
No specific regional macro linkage beyond US healthcare services.
Limited, as the disclosed drivers are company-specific (billing transition, customer internalization, acquisitions).
Counterpoint
Sequential revenue and anatomic pathology strength may indicate the integration is working, and the guidance cut could be a temporary timing issue from billing system go-live.
Key entities
- companyFulgent Genetics, Inc.
Reported Q2 2026 results and revised full-year guidance due to billing system transition headwinds; discussed clinical and platform milestones.
- personMing Hsieh
CEO who discussed FDA Phase II meeting confirmation for FID-007 and Phase III timing expectations.
- personPaul Kim
CFO who attributed gross margin decline to fixed costs over a lower revenue base from reduced collection rates.
- personBrandon Perthuis
Chief Commercial Officer who discussed Epic Aura early-adopter go-live timing and anatomic pathology digital pathology focus.
